Cabaletta Bio, Inc. Announces 2024 Annual Meeting of Stockholders
Ticker: CABA · Form: DEF 14A · Filed: Apr 23, 2024 · CIK: 1759138
Sentiment: neutral
Topics: Proxy Statement, Annual Meeting, Director Election, Auditor Ratification, Virtual Meeting
TL;DR
<b>Cabaletta Bio, Inc. will hold its 2024 Annual Meeting of Stockholders virtually on June 3, 2024, to elect directors and ratify auditors.</b>
AI Summary
Cabaletta Bio, Inc. (CABA) filed a Proxy Statement (DEF 14A) with the SEC on April 23, 2024. Cabaletta Bio, Inc. will hold its 2024 Annual Meeting of Stockholders virtually on June 3, 2024, at 9:00 a.m. Eastern Time. The meeting will allow stockholders to elect two class II directors to the board. Stockholders will also vote to ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2024. The record date for stockholders entitled to vote is April 4, 2024. Proxy materials are being furnished via the Internet under the SEC's 'Notice and Access' rule.
Why It Matters
For investors and stakeholders tracking Cabaletta Bio, Inc., this filing contains several important signals. The election of directors and ratification of auditors are key governance activities that directly impact the company's strategic direction and financial oversight. The virtual format and 'Notice and Access' rule affect how stockholders can participate and receive information, highlighting the company's adoption of modern communication practices.
Risk Assessment
Risk Level: low — Cabaletta Bio, Inc. shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting, with no immediate financial or operational risks disclosed.
Analyst Insight
Stockholders should review the director nominees and auditor ratification to make informed voting decisions at the upcoming annual meeting.
Key Numbers
- 2 — Directors to be elected (To elect two class II directors)
- 2024 — Fiscal Year End (Fiscal year ending December 31, 2024)
- 2027 — Director Term (Serve until the 2027 annual meeting)
Key Players & Entities
- Cabaletta Bio, Inc. (company) — Registrant name
- Ernst & Young LLP (company) — Independent registered public accounting firm
- June 3, 2024 (date) — Date of Annual Meeting
- April 4, 2024 (date) — Record date for voting
- 2024 (date) — Fiscal year
FAQ
When did Cabaletta Bio, Inc. file this DEF 14A?
Cabaletta Bio, Inc. filed this Proxy Statement (DEF 14A) with the SEC on April 23, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by Cabaletta Bio, Inc. (CABA).
Where can I read the original DEF 14A filing from Cabaletta Bio, Inc.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Cabaletta Bio, Inc..
What are the key takeaways from Cabaletta Bio, Inc.'s DEF 14A?
Cabaletta Bio, Inc. filed this DEF 14A on April 23, 2024. Key takeaways: Cabaletta Bio, Inc. will hold its 2024 Annual Meeting of Stockholders virtually on June 3, 2024, at 9:00 a.m. Eastern Time.. The meeting will allow stockholders to elect two class II directors to the board.. Stockholders will also vote to ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2024..
Is Cabaletta Bio, Inc. a risky investment based on this filing?
Based on this DEF 14A, Cabaletta Bio, Inc. presents a relatively low-risk profile. The filing is a routine proxy statement for an annual meeting, with no immediate financial or operational risks disclosed.
What should investors do after reading Cabaletta Bio, Inc.'s DEF 14A?
Stockholders should review the director nominees and auditor ratification to make informed voting decisions at the upcoming annual meeting. The overall sentiment from this filing is neutral.
How does Cabaletta Bio, Inc. compare to its industry peers?
Cabaletta Bio, Inc. is a biotechnology company focused on developing therapies for debilitating autoimmune and hematologic diseases.
Are there regulatory concerns for Cabaletta Bio, Inc.?
The filing adheres to SEC regulations for proxy statements, including disclosure requirements for annual meetings and corporate governance.
Industry Context
Cabaletta Bio, Inc. is a biotechnology company focused on developing therapies for debilitating autoimmune and hematologic diseases.
Regulatory Implications
The filing adheres to SEC regulations for proxy statements, including disclosure requirements for annual meetings and corporate governance.
What Investors Should Do
- Review the biographies and qualifications of the director nominees.
- Evaluate the rationale for ratifying Ernst & Young LLP as the independent auditor.
- Register and attend the virtual annual meeting to cast your vote.
Key Dates
- 2024-06-03: Annual Meeting of Stockholders — Election of directors and ratification of auditors
- 2024-04-04: Record Date — Stockholders of record entitled to vote
Year-Over-Year Comparison
This is the initial filing for the 2024 Annual Meeting of Stockholders.
Filing Stats: 4,927 words · 20 min read · ~16 pages · Grade level 11.4 · Accepted 2024-04-23 07:00:57
Key Financial Figures
- $1.235 billion — gross revenue is equal to or more than $1.235 billion; (iii) the date on which we have issued
- $1 billion — date on which we have issued more than $1 billion in nonconvertible debt during the previ
- $0.00001 — s of our voting common stock, par value $0.00001 per share, outstanding on April 4, 2024
Filing Documents
- d448465ddef14a.htm (DEF 14A) — 381KB
- g448465dsp2.jpg (GRAPHIC) — 1KB
- g448465dsp2a.jpg (GRAPHIC) — 9KB
- g448465dsp2b.jpg (GRAPHIC) — 81KB
- g448465dsp2c.jpg (GRAPHIC) — 18KB
- g448465dsp2d.jpg (GRAPHIC) — 3KB
- g448465dsp2e.jpg (GRAPHIC) — 2KB
- g448465dsp2f.jpg (GRAPHIC) — 2KB
- g448465dsp2g.jpg (GRAPHIC) — 3KB
- g448465dsp3a.jpg (GRAPHIC) — 9KB
- g448465dsp3c.jpg (GRAPHIC) — 1KB
- g448465g01a02.jpg (GRAPHIC) — 34KB
- 0001193125-24-105870.txt ( ) — 610KB
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION 24 DIRECTOR COMPENSATION 31 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 33 PRINCIPAL STOCKHOLDERS 35 REPORT OF THE AUDIT COMMITTEE 37 DELINQUENT SECTION 16(a) REPORTS 38 HOUSEHOLDING 39 STOCKHOLDER PROPOSALS 39 OTHER MATTERS 40 i Table of Contents CABALETTA BIO, INC. 2929 Arch Street, Suite 600 Philadelphia, PA 19104 PROXY STATEMENT FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD JUNE 3, 2024 This proxy statement contains information about the 2024 Annual Meeting of Stockholders, or the Annual Meeting, of Cabaletta Bio, Inc., which will be held online on June 3, 2024 at 9:00 a.m. Eastern Time. You may attend the Annual Meeting virtually via the Internet at www.proxydocs.com/CABA, where you will be able to vote electronically and submit questions. The board of directors of Cabaletta Bio, Inc. is using this proxy statement to solicit proxies for use at the Annual Meeting. In this proxy statement, the terms Cabaletta, the Company, we, us, and our refer to Cabaletta Bio, Inc. The mailing address of our principal executive offices is Cabaletta Bio, Inc., 2929 Arch Street, Suite 600, Philadelphia, PA 19104. All properly submitted proxies will be voted in accordance with the instructions contained in those proxies. If no instructions are specified, the proxies will be voted in accordance with the recommendation of our board of directors with respect to each of the matters set forth in this proxy statement and the accompanying proxy card. You may revoke your proxy at any time before it is exercised at the meeting by giving our corporate secretary written notice to that effect. We are mailing to our stockholders a Notice of Internet Availability of proxy materials and our 2023 Annual Report on or about April 23, 2024. We are an emerging growth company under applicable federal securities laws and therefore permitted to conform with certain reduced public company reporting requirem